Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62 in Healthy Adults
NCT00820846Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2009
- Primary completion
- Aug 2012
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of pGA2/JS7 DNA vaccine, MVA/HIV62B in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2009; status: completed.
02
Drugs
pGA2/JS7 DNA vaccineMVA/HIV62B
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00820846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820846.